CareDx Inc. filed a patent infringement suit against Eurofins Viracor Inc. in the U.S. District Court for Delaware over technology used for organ transplants.
Brisbane, Calif.-based CareDx is asserting U.S. Patent No. 8,703,652 — exclusively licensed to the company from Stanford University — which covers non-invasive monitoring of organ transplant rejection through cell-free DNA analysis.
CareDx alleges that Eurofins Viracor infringes on the patent by selling a test that performs an analysis of cell-free DNA from patients who have undergone organ transplants to inform on rejection of the organ.
The company said it is pursuing all available remedies, including damages and injunction.
